Core Viewpoint - The mosquito-repellent concept stocks continue to show strong performance, driven by the reported cases of Chikungunya fever in Foshan, with a total of 3,195 confirmed cases as of July 22, primarily concentrated in Shunde District [1] Group 1: Company Performance - Rainbow Group has achieved a consecutive two-day increase in stock price [1] - Kangzhi Pharmaceutical has seen a rise of over 10% in its stock price [1] - Other companies such as Runben Co., Wanfang Biological, Shanghai Jahwa, Qingsong Co., and Lafang Co. have also experienced stock price increases [1]

Group 1: Infrastructure and Construction Industry - The overall infrastructure investment in China continued to show steady growth in the first half of 2025, with a year-on-year increase of 8.9% for broad infrastructure and 4.6% for narrow infrastructure [9][10] - The Yarlung Tsangpo River Super Hydropower Project, with a total investment of 1.2 trillion yuan, has officially commenced, marking a significant step in clean energy development under complex geological conditions [10] - The Central Urban Work Conference highlighted a shift in urbanization from rapid expansion to quality improvement, indicating potential systematic development opportunities in urban renewal and infrastructure upgrades [10][12] Group 2: Real Estate Industry - The real estate sector experienced a decline of 2.2% this week, with new housing transactions in 42 key cities dropping by 10.8% compared to the previous week [14][15] - The Central Urban Work Conference emphasized the need for urban renewal as a key strategy, with a focus on transforming the real estate development model and promoting the renovation of old neighborhoods [16] - National real estate development investment decreased by 11.2% year-on-year in the first half of 2025, indicating a need for stronger measures to stabilize the market [16] Group 3: Electronics Industry - The company Juzan Optoelectronics reported a revenue of 1.594 billion yuan in the first half of 2025, representing a year-on-year growth of 19.51%, with net profit increasing by 3.43% [19][20] - The company is transitioning to a full-color LED chip manufacturer, with a focus on high-value-added products, which is expected to enhance profit margins [20][21] - The production capacity for red and yellow light is rapidly increasing, contributing to the establishment of a second growth curve for the company [20][21] Group 4: New Consumption Sector - Runben Co., Ltd. is expected to benefit from increased demand for mosquito prevention products due to a local outbreak of Chikungunya fever in Guangdong [23][24] - The company launched over 90 new products in 2024, targeting differentiated consumer needs, with significant revenue contributions from its mosquito and infant product lines [24] - The company is well-positioned in the market due to its established brand image and competitive pricing strategy, which is likely to sustain high growth rates [24] Group 5: Non-Banking Financial Sector - Xinhua Insurance reported a 19% year-on-year increase in net profit for Q1 2025, driven by a 28% growth in original premium income [26][27] - The company has significantly increased its equity investment allocation, with a notable rise in the proportion of equity assets in its investment portfolio [27][28] - The company is expected to issue perpetual bonds to enhance its capital strength, given its high equity asset ratio [28][30]

Market Overview - The market experienced fluctuations with mixed performance across the three major indices, with the Shanghai Composite Index briefly surpassing 3600 points before retreating [1] - The overall market saw a high rate of stock volatility, with a 50% rate of stocks hitting their daily limit down [1] - The total trading volume for the day reached 1.9 trillion yuan [1] Hot Topics Yarlung Tsangpo River Hydropower Project - Stocks related to the Yarlung Tsangpo River hydropower project continued to surge, with companies like China Power Construction and Huaxin Cement hitting their daily limit up [4] - The project has garnered significant market attention, leading to a valuation recovery for infrastructure stocks due to low valuations and high dividend yields [5] Consumer Sector - The consumer sector showed strong activity, with companies such as Hanchang Group and Nanjing New百 hitting their daily limit up [6] - The World Health Organization raised alarms regarding the spread of the chikungunya virus, which could impact public health and consumer behavior [6] Nuclear Fusion Sector - The nuclear fusion sector saw notable movements, with companies like GuoJi Heavy Industry and XueRen Group experiencing significant gains [8] - The establishment of China Fusion Energy Co., a subsidiary of China National Nuclear Corporation, was announced, with an investment of approximately 11.49 billion yuan from various stakeholders [8] Stock Performance Yarlung Tsangpo River Project Stocks - Key stocks in this sector included: - ShanHe Intelligent: 10.67 yuan, +10.00%, market cap 11.445 billion yuan - Tibet Tianlu: 12.75 yuan, +10.01%, market cap 16.93 billion yuan - Deep Water Regulation Institute: 27.82 yuan, +20.02%, market cap 6.206 billion yuan [5][16] Consumer Sector Stocks - Notable performers included: - Hanchang Group: 10.92 yuan, +9.97%, market cap 3.22 billion yuan - Nanjing New百: 7.55 yuan, +10.06%, market cap 8.796 billion yuan - Rainbow Group: 22.65 yuan, +10.00%, market cap 2.38 billion yuan [7][16] Nuclear Fusion Stocks - Key stocks included: - GuoJi Heavy Industry: 4.09 yuan, +9.95%, market cap 29.503 billion yuan - XueRen Group: 11.44 yuan, +10.00%, market cap 7.443 billion yuan [9][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to benefit from the synergy in the mosquito repellent and baby care segments, with a comprehensive channel layout expanding performance potential [5] - The company has launched over 90 new products in 2024, catering to differentiated consumer needs, which is anticipated to drive revenue growth [8] - The company has established a strong brand image in the domestic market and is expected to maintain high growth through a refined brand matrix and competitive pricing strategy [8] Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 1,033 million RMB - 2024: 1,318 million RMB (YoY growth of 27.61%) - 2025: 1,771 million RMB (YoY growth of 34.33%) - 2026: 2,246 million RMB (YoY growth of 26.84%) - 2027: 2,759 million RMB (YoY growth of 22.84%) [7] - Net profit projections are as follows: - 2023: 226 million RMB - 2024: 300 million RMB (YoY growth of 32.80%) - 2025: 389 million RMB (YoY growth of 29.45%) - 2026: 490 million RMB (YoY growth of 25.99%) - 2027: 605 million RMB (YoY growth of 23.61%) [7] - Earnings per share (EPS) projections are: - 2023: 0.56 RMB - 2024: 0.74 RMB - 2025: 0.96 RMB - 2026: 1.21 RMB - 2027: 1.50 RMB [7] Market Data - As of July 22, 2025, the closing price of the stock is 29.63 RMB, with a market capitalization of 11,988.10 million RMB and a circulating market value of 3,061.85 million RMB [3] - The company's asset-liability ratio stands at 7.69% and the net asset value per share is 5.25 RMB [3]

美容护理板块走高，润本股份（603193）涨停，嘉亨家化（300955）涨超10%，上海家化（600315）、 华业香料（300886）、拉芳家化（603630）、芭薇股份、可靠股份（301009）等跟涨。 ...

Investment Rating - The industry maintains a "Recommended" rating, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][35]. Core Insights - The total retail sales of consumer goods in China for the first half of 2025 reached 24.55 trillion yuan, showing a year-on-year increase of 5%. In June, the retail sales totaled 4.23 trillion yuan, growing by 4.8% year-on-year, which was below the expected 8.4% due to the timing of the Dragon Boat Festival and the pre-release of demand during the 618 shopping festival [3][23]. - The beauty care sector is highlighted with significant developments, including the strategic expansion of Ai Er Bo Shi in Southeast Asia and the announcement of a new CEO at Kenvue [27][3]. - Bubble Mart is expected to see a revenue increase of no less than 200% and a profit increase of no less than 350% for the first half of 2025 [32][5]. Summary by Sections Market Performance - From July 14 to July 18, 2025, the trade retail, social services, and beauty care sectors experienced changes of +0.23%, +1.05%, and -0.14% respectively, ranking 18th, 13th, and 22nd among 31 primary industries [14][16]. Key Industry Data and News - In June 2025, the retail sales of consumer goods grew by 4.8%, with a total of 21.8 trillion yuan in goods retail sales for the first half of the year, reflecting a 5.1% year-on-year increase [23][22]. - The airline industry saw an increase in passenger flights, with nearly 118,000 flights executed nationwide in the 28th week of 2025, marking a 3.2% year-on-year rise [4][27]. Company Announcements - Bubble Mart's half-year performance forecast indicates a revenue growth of at least 200% and a profit increase of at least 350% [32][5]. - Other companies like Rongzi Co. and Longzi Co. also reported significant profit forecasts, with Rongzi expecting a profit increase of 31.74% to 55.69% [34][33]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzi Bio, Marumi Bio, and others within the beauty care and new consumption sectors [5][35].

Core Viewpoint - The AI Fund Minsheng Jianyin Dividend Return Mixed Fund (690009) reported a profit of 2.2766 million yuan for Q2 2025, with a net asset value growth rate of 4.33% during the period [3] Fund Performance - As of the end of Q2 2025, the fund's scale was 54.2078 million yuan [15] - The fund's weighted average profit per share for the period was 0.1049 yuan [3] - The fund's unit net value as of July 21 was 2.505 yuan [3] - The fund's one-year cumulative net value growth rate was 6.05%, ranking 732 out of 880 comparable funds [3] - The fund's three-month net value growth rate was 4.02%, ranking 757 out of 880 comparable funds [3] - The fund's six-month net value growth rate was 5.25%, ranking 598 out of 880 comparable funds [3] - The fund's three-year net value growth rate was -23.05%, ranking 672 out of 871 comparable funds [3] Investment Strategy - The fund manager, Deng Kaicheng, maintains a positive outlook on value style and dividends, focusing on stable investments while seeking flexible dividend opportunities [3] - The fund continues to allocate a significant portion to the financial sector and actively seeks companies with improved operations and higher dividend payouts [3] Risk Metrics - The fund's three-year Sharpe ratio was -0.3336, ranking 749 out of 875 comparable funds [8] - The maximum drawdown over the past three years was 33.6%, ranking 513 out of 873 comparable funds [10] - The maximum drawdown in a single quarter occurred in Q1 2021, reaching 18.96% [10] Portfolio Composition - The average stock position over the past three years was 74.32%, compared to the industry average of 80.43% [13] - The fund reached its highest stock position of 77.33% at the end of H1 2024, with a lowest position of 35.27% at the end of Q1 2019 [13] - As of Q2 2025, the fund's top ten holdings included companies such as Chao Hong Ji, Zhong Chong Co., Runben Co., and Meidi Group [17]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting innovative business models driving growth in the light medical beauty sector, particularly recommending attention to the company "Xinyang" [2][9]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 0.1% from July 11 to July 18, 2025, while the Shenwan Cosmetics Index fell by 0.9%, underperforming the Shenwan A Index by 2.3 percentage points [3][4]. - Innovative business models are driving growth in light medical beauty, contrasting with traditional medical beauty institutions facing stagnation due to high costs and weak consumer demand. Xinyang's high cost-performance ratio, chain operations, and app-based customer conversion model are seen as new growth drivers for the sector [9][10]. - The report emphasizes the importance of supply-side innovations in stimulating consumer demand and driving industry recovery, despite short-term macroeconomic challenges [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weak performance compared to the market, with specific indices reflecting declines during the reporting period [3][4]. - The top-performing stocks in the sector included Zhongshun Jierou (+10.8%) and Juzibio (+6.1%), while the worst performers were Shangmei Shares (-11.1%) and Baiya Shares (-4.3%) [5]. Key Company Insights - Linqingxuan, a high-end domestic skincare brand, has seen revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [10][15]. - The company has established a strong product matrix and supply chain advantages, with production capacity reaching 40 million units annually [16][17]. - The report also highlights the growth of the "Plant Doctor" brand, which has achieved a net profit CAGR of 24% from 2022 to 2024, supported by a robust channel network and operational efficiencies [10][12]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of total cosmetics sales in 2024, up from 22% in 2016 [11]. - The domestic market is witnessing a rise in local brands, with a notable increase in market share for domestic products, reflecting changing consumer preferences and the impact of the "national tide" [11][28]. Financial Performance - The report indicates that the overall retail sales of cosmetics in China reached 229.1 billion yuan in the first half of 2025, with a year-on-year growth of 2.9%, although June saw a decline of 2.3% due to promotional timing [21][24]. - The performance of major companies like Meili Tianyuan is highlighted, with projected revenue of at least 1.45 billion yuan for the first half of 2025, representing a growth of at least 27% [24].

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty industry, indicating a "Buy" recommendation for several companies within the sector [2][14]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Beauty Care Index rising by 1.5% from July 4 to July 11, 2025, which is below the market average [3][5]. - The introduction of new products in the regenerative medicine sector, particularly in the "童颜针" (youthful needle) category, is expected to enhance consumer interest and expand the market [2][8]. - The report highlights strong anticipated earnings growth for several key companies in the cosmetics sector for the second quarter of 2025, with notable increases in revenue and net profit for brands like 上美股份 (Shangmei), 丸美股份 (Marubi), and 珀莱雅 (Proya) [9][10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing varied performance, such as the Shenwan Cosmetics Index increasing by 2.6% [3][5]. - The report notes that the demand for cosmetics is recovering, with a 4.1% year-on-year increase in retail sales for the first five months of 2025 [19][20]. Company Performance - 上美股份 (Shangmei) is expected to see a revenue increase of 16% and a net profit increase of 25% in the first half of 2025 [10]. - 丸美股份 (Marubi) anticipates a 22% revenue growth and a 28% increase in net profit for the second quarter of 2025 [10]. - 珀莱雅 (Proya) is projected to achieve a 10% revenue growth and a 15% increase in net profit for the second quarter of 2025 [10]. - 毛戈平 (Mao Geping) expects a significant revenue increase of 38% and a net profit increase of 35% in the first half of 2025 [10]. - 若羽臣 (Ruoyuchen) forecasts a remarkable 70% revenue growth and a 75% increase in net profit for the second quarter of 2025 [10]. Market Trends - The report emphasizes the ongoing trend of domestic brands gaining market share, with national brands occupying five of the top ten positions in the skincare market [32]. - The regenerative medicine sector is expanding, with new products enhancing consumer engagement and market growth potential [2][8]. Investment Recommendations - The report recommends focusing on companies with strong brand matrices and high growth potential, such as 上美股份 (Shangmei), 珀莱雅 (Proya), and 丸美股份 (Marubi) [14]. - It suggests monitoring companies that leverage e-commerce and social media platforms effectively, such as 若羽臣 (Ruoyuchen) and 毛戈平 (Mao Geping) [14].

Summary of Key Points Core Viewpoint - JNRY VIII HK Holdings Limited, a major shareholder of Runben Biotechnology Co., Ltd., has completed a share reduction plan, selling a total of 3,608,400 shares, which is 0.89% of the company's total share capital [2][3][4]. Group 1: Shareholder Holding Situation - Before the reduction plan, JNRY VIII held 22,252,566 shares, accounting for 5.50% of the total share capital of the company [2]. Group 2: Reduction Plan Implementation Results - The reduction plan announced on March 19, 2025, allowed JNRY VIII to reduce up to 12,137,799 shares (3.00% of total share capital) through both centralized bidding and block trading [3]. - The actual reduction was completed within the specified timeframe, and the total shares reduced were consistent with the previously disclosed plan [4]. - The reduction included a maximum of 4,045,933 shares through centralized bidding (1.00% of total share capital) and 8,091,866 shares through block trading (2.00% of total share capital) [3].